Oocyte Retrieval in IVF: Understanding Procedure-Related Risks and the Importance of Device Safety

Oocyte retrieval, also called ovum pick-up (OPU) or transvaginal oocyte retrieval (TVOR), is a critical step in in-vitro fertilization (IVF). The procedure is generally brief and minimally invasive, but it is not risk-free. Because the aspiration needle passes through the vaginal wall and into the ovary under ultrasound guidance, accurate visualization, controlled needle movement, appropriate aspiration, infection prevention, and reliable device performance all contribute to procedural safety.

For fertility specialists, therefore, oocyte retrieval safety is not determined by clinical technique alone. It is the result of an integrated system involving patient assessment, ultrasound guidance, operator experience, aspiration technique, anesthesia or analgesia, infection-control measures, and the quality and intended use of the medical devices involved.

This article reviews the principal risks associated with transvaginal oocyte retrieval and explains the practical characteristics of an oocyte aspiration needle that should be considered when selecting medical devices for IVF practice.

 

What happens during oocyte retrieval?

In a conventional IVF cycle, controlled ovarian stimulation is followed by final oocyte maturation. When the follicles have reached the appropriate stage, oocyte retrieval is performed, usually approximately 34–36 hours after the final maturation trigger, according to the clinic's protocol.

During transvaginal retrieval, a transvaginal ultrasound probe is used to visualize the ovaries and follicles. An aspiration needle attached to an aspiration system is guided through the vaginal wall toward the follicles. Follicular fluid is aspirated, collected in appropriate tubes or containers, and immediately transferred to the embryology laboratory, where the aspirate is examined for oocytes.

ESHRE's good-practice recommendations emphasize preparation, ultrasound visualization, needle positioning, aspiration technique, and post-procedure care as interconnected components of safe oocyte retrieval.

The procedure may appear straightforward, but the anatomical structures involved are highly vascularized and lie close to the bladder, bowel, pelvic vessels, and other organs. This makes controlled needle placement particularly important.

 

How safe is oocyte retrieval?

Serious complications are uncommon, but they can occur.

Reported complications of transvaginal oocyte retrieval include vaginal or intra-abdominal bleeding, pelvic infection, injury to adjacent organs, ovarian or adnexal torsion, and complications related to anesthesia or sedation. A comprehensive review of TVOR complications identified hemorrhage, pelvic-organ injury, and pelvic infection among the principal procedure-related concerns.

ASRM has reported that acute complications such as pelvic infection, intraperitoneal hemorrhage, and ovarian torsion are uncommon, with reported rates below 0.5% in the context discussed by its committee opinion.

The precise risk varies between studies and depends on the patient population, definition of a complication, operator experience, ovarian anatomy, number of follicles, previous pelvic surgery or infection, and the clinical protocol used.

Consequently, the correct objective is not to claim that complications can be completely prevented. The practical objective is to identify foreseeable hazards and reduce avoidable risk through appropriate patient selection, standardized technique, trained personnel, and reliable medical devices.

 

The main procedure-related risks

1. Bleeding

Minor vaginal spotting or limited bleeding can occur following needle passage through the vaginal wall. More significant bleeding can arise from injury to ovarian or pelvic vessels.

Severe intra-abdominal bleeding is rare, but it is one of the most clinically important complications because it can require observation, transfusion, interventional treatment, or surgery. A systematic review of severe hemoperitoneum caused by ovarian bleeding after TVOR reported an incidence of approximately 0.08% among the published clinical data analyzed. Most cases became evident within the first 24 hours.

Practical risk-reduction measures include:

• Careful ultrasound identification of the ovary and surrounding anatomy.
• Avoidance of unnecessary needle passes.
• Controlled needle advancement.
• Appropriate needle visualization throughout the procedure.
• Use of a sharp, predictable needle tip.
• Appropriate aspiration technique.
• Post-procedure observation according to the clinic's protocol.

The design of the needle does not eliminate bleeding risk, but predictable needle behavior and good ultrasound visibility can support controlled needle placement.

2. Pelvic infection

Pelvic infection following oocyte retrieval is uncommon but potentially serious.

The needle crosses the vaginal environment before entering the ovary, creating a theoretical route for microorganisms to reach pelvic structures. Risk may be higher in selected patients, including those with previous pelvic inflammatory disease, significant pelvic adhesions, or certain forms of endometriosis.

Infection prevention therefore requires more than a sterile needle. It includes appropriate patient assessment, preparation of the procedural field, adherence to the clinic's infection-control protocol, appropriate device packaging and sterility assurance, and correct handling of the device.

For single-use sterile devices, the integrity of the package is particularly important. A damaged, wet, opened, or otherwise compromised sterile barrier should not be treated as equivalent to an intact sterile package.

WHO emphasizes that medical-device regulation and quality systems are intended to ensure the safety, quality, and performance of medical devices throughout their lifecycle.

3. Injury to adjacent organs

The ovary is located close to other pelvic structures. Depending on anatomy, ovarian position, follicle distribution, previous surgery, adhesions, or other clinical factors, the needle trajectory may be more challenging.

Potential injuries include trauma to the bladder, bowel, blood vessels, or other pelvic structures.

Bladder injury is particularly rare but illustrates why accurate needle visualization and controlled advancement matter. A recent review identified a pooled incidence of approximately 0.02% for bladder hematoma associated with TVOR in the literature it analyzed.

The key principle is straightforward: the needle should be advanced only when its trajectory and target are adequately visualized.

4. Pain and patient discomfort

Although analgesia and sedation protocols can make retrieval well tolerated, pain remains an important patient-centered consideration.

Needle diameter and tip design can influence procedural discomfort. Randomized trials have reported lower pain scores with smaller-diameter or reduced-tip needles compared with larger standard needles, without a demonstrated adverse effect on oocyte recovery or pregnancy outcomes in the studied populations.

A systematic review and meta-analysis of six randomized controlled trials involving 1,063 patients found that reduced needles were associated with lower pain scores, lower analgesic requirements, and less vaginal bleeding than standard needles, without a significant difference in clinical pregnancy rate.

However, needle diameter should not be considered in isolation. The appropriate needle configuration depends on the aspiration system, follicular characteristics, operator preference, device design, and the validated intended use of the product.

 

Why ultrasound visibility matters

Ultrasound guidance is fundamental to modern transvaginal oocyte retrieval.

The clinician needs to identify the follicle, visualize the needle, control its trajectory, and position the tip appropriately before aspiration.

Poor needle visualization can make accurate positioning more difficult, particularly when the needle is approaching the ovary at an unfavorable angle or when the anatomy is challenging.

For this reason, echogenic needle features are not simply a convenience. They are a design characteristic intended to improve visualization under ultrasound.

ESHRE's recommendations specifically address ultrasound practice during oocyte retrieval and provide guidance covering preparation, the retrieval procedure, and post-procedure management.

In practical terms, clinicians evaluating an aspiration needle should consider:

• Visibility of the needle shaft and tip under the ultrasound system used in the clinic.
• Consistency of echogenic markings or features.
• Visibility at clinically relevant needle angles.
• Ability to identify the needle tip accurately.
• Stability of the needle during advancement.
• Compatibility with the clinic's ultrasound-guided retrieval technique.

 

Why needle design matters

An oocyte aspiration needle is a relatively small device, but several design characteristics can influence its clinical handling.

Tip geometry

A sharp and consistent tip can facilitate controlled tissue penetration. Manufacturing consistency is important because variations in tip geometry can affect handling characteristics.

Echogenicity

Ultrasound-visible markings or an appropriately designed echogenic tip can help the clinician identify the needle during the procedure.

Flexibility and stiffness

The needle needs sufficient flexibility to accommodate the procedural trajectory while maintaining enough structural stability for controlled positioning.

Too much flexibility can make precise manipulation difficult; excessive rigidity may affect handling and tissue interaction. The appropriate balance depends on the complete needle design and intended clinical application.

Aspiration performance

The needle must function as part of an aspiration system. Consistent fluid flow, secure connections, and predictable aspiration behavior are important for efficient follicular aspiration.

The aspiration system should be used according to the manufacturer's instructions and the validated operating parameters of the device.

Hub and connection security

The connection between the needle and aspiration tubing should remain secure throughout the procedure. A reliable hub design reduces the risk of disconnection, leakage, or interruption of aspiration.

Sterility and packaging

For a sterile single-use device, the sterile barrier is part of the product's safety system.

The device should be individually packaged as specified by the manufacturer, with appropriate sterilization and validated shelf life. Before use, clinical staff should verify packaging integrity, expiration information, product identification, and any applicable lot or batch information.

Traceability

Traceability is an important part of medical-device quality management. Clinics should be able to identify which device or product lot was used when required by their quality-management, complaint-handling, or incident-investigation procedures.

 

Single-lumen versus double-lumen aspiration needles

Oocyte aspiration needles are available in different configurations, including single-lumen and double-lumen designs.

The appropriate configuration depends on the clinical technique and the intended application.

A single-lumen needle provides a straightforward aspiration pathway and is commonly used for routine follicular aspiration.

Double-lumen systems can provide an additional channel that may be used for follicular flushing, depending on the clinical protocol and device configuration.

The choice should therefore be based on the clinic's established retrieval protocol rather than on the assumption that one configuration is universally superior.

The device must also be compatible with the aspiration equipment, tubing, flushing system, and other components used by the clinic.

 

Device safety is more than sterility

When fertility clinics evaluate an oocyte aspiration needle, sterility is essential—but it is only one part of device safety.

A practical evaluation should cover at least five areas:

1. Patient safety

Consider needle geometry, tissue interaction, ultrasound visibility, sterility, biocompatibility, and the potential for avoidable procedural trauma.

2. Clinical performance

Assess whether the device provides predictable aspiration, stable connections, appropriate handling, and consistent performance across the intended range of use.

3. Manufacturing quality

A reliable medical device depends on controlled manufacturing processes, material specifications, inspection, validation, and release criteria.

4. Regulatory and quality documentation

Clinics and distributors should have access to appropriate product documentation, including instructions for use, specifications, sterilization information, shelf life, applicable regulatory documentation, and complaint or adverse-event reporting pathways.

5. Traceability and post-market surveillance

A responsible device manufacturer should have processes for monitoring product performance after market release and investigating complaints, incidents, or quality concerns.

WHO identifies quality, safety, and performance as central objectives of medical-device regulatory systems.

 

What should fertility clinics check before using an aspiration needle?

A practical pre-use checklist can help standardize device selection and preparation.

Before the procedure, clinical teams should verify:

• Correct needle model and configuration.
• Correct gauge and length for the intended procedure.
• Sterile package integrity.
• Expiration date and product identification.
• Compatibility with the aspiration tubing and equipment.
• Availability of the appropriate ultrasound-guidance setup.
• Correct connection between the needle and aspiration system.
• Availability of required flushing and collection materials.
• Familiarity of the operator with the device's instructions for use.
• Documentation and traceability requirements according to the clinic's quality system.

For reusable medical devices, reprocessing is an additional safety consideration. FDA guidance emphasizes that reusable devices require validated cleaning, disinfection, or sterilization processes appropriate to the device and that manufacturers should provide clear, scientifically validated reprocessing instructions.

For single-use oocyte aspiration needles, the appropriate approach is different: they should be used according to their labeling and intended use, and single-use status should not be bypassed through informal or unvalidated reuse practices.

 

What should happen after retrieval?

Safe oocyte retrieval does not end when the needle is withdrawn.

The patient should be monitored according to the clinic's post-procedure protocol, with particular attention to symptoms that could indicate a complication.

Patients should receive clear instructions about when to contact the clinic or seek urgent medical attention. Concerning symptoms can include:

• Severe or increasing abdominal or pelvic pain.
• Heavy vaginal bleeding.
• Dizziness, fainting, marked weakness, or symptoms suggestive of significant blood loss.
• Fever or chills.
• Persistent vomiting or significant abdominal distension.
• Difficulty urinating or visible blood in the urine.
• Shortness of breath or other symptoms requiring urgent assessment.

The specific clinical response should follow the fertility center's emergency and post-retrieval protocols.

 

Oocyte retrieval safety is a system, not a single feature

It is tempting to describe a medical device as "safe" based on one characteristic—such as a sharp tip, echogenic marking, small diameter, or sterile packaging.

Clinical safety is more complex.

A high-quality oocyte aspiration needle must perform consistently as part of a complete clinical workflow. Its design, materials, manufacturing process, sterilization, packaging, labeling, compatibility, and post-market quality system all contribute to the overall safety profile.

At the same time, no device can substitute for appropriate patient assessment, ultrasound expertise, procedural training, infection-control practice, or clinical judgment.

The strongest approach is therefore a systems-based one: select a device with appropriate design and documented quality, use it according to its intended purpose and instructions, standardize the retrieval workflow, monitor outcomes, and investigate deviations or adverse events.

 

Choosing an oocyte aspiration needle: a practical framework

For fertility centers, the following questions can help structure device evaluation:

Visibility: Can the operator consistently identify the needle tip under ultrasound?

Control: Does the needle provide predictable handling and trajectory control?

Aspiration: Does it provide consistent and reliable follicular aspiration when used with the intended aspiration system?

Tissue interaction: Is the needle geometry appropriate for controlled transvaginal access and follicular aspiration?

Patient experience: Has the design been evaluated with regard to pain or bleeding where relevant?

Sterility: Is the device supplied sterile with an appropriate validated sterilization process and intact sterile barrier?

Quality: Does the manufacturer operate an appropriate medical-device quality-management system?

Traceability: Can the product and relevant production lot be identified?

Documentation: Are the instructions for use, specifications, regulatory information, and safety documentation readily available?

Consistency: Can the manufacturer demonstrate reliable production and quality control rather than relying only on a prototype or individual product sample?

These questions move the selection process from simply comparing product specifications toward evaluating the complete clinical and quality system surrounding the device.

 

RADA and oocyte aspiration

RADA develops medical devices for assisted reproduction and women's health, including single-lumen and double-lumen ovum aspiration needles.

The RADA Single Lumen Oocyte Aspiration Needle is designed for ultrasound-guided oocyte retrieval and incorporates features intended to support visualization, handling, and controlled aspiration. The product is supplied sterile and individually packaged, with multiple gauge and length configurations available.

View RADA Oocyte Aspiration Needles

For fertility centers, the most important consideration is not simply selecting a needle with more features. It is selecting a device whose design, specifications, documentation, quality controls, and intended use are appropriate for the clinic's established retrieval workflow.

 

Conclusion

Transvaginal oocyte retrieval is an established and generally safe component of IVF, but it involves real procedural risks. Bleeding, infection, pain, and injury to adjacent structures are uncommon but clinically relevant complications that require appropriate prevention, recognition, and management.

Device selection is one component of this risk-management process.

A well-designed oocyte aspiration needle should provide predictable handling, appropriate ultrasound visibility, reliable aspiration performance, secure connections, appropriate tissue interaction, and validated sterility and packaging. These characteristics must be supported by controlled manufacturing, quality management, appropriate documentation, and post-market monitoring.

For IVF clinics, the practical objective is therefore not simply to find an "advanced" aspiration needle. It is to use a reliable medical device as part of a standardized, evidence-based retrieval system in which patient assessment, ultrasound guidance, operator technique, infection control, device performance, and post-procedure monitoring work together.

In assisted reproduction, every procedural detail matters. Reliable device performance is one of the foundations on which safe and consistent clinical practice is built.

 

 

References

1. D'Angelo A, Panayotidis C, Amso N, et al. Recommendations for good practice in ultrasound: oocyte pick up. Human Reproduction Open. 2019;2019(4):hoz025.
2. Tarlatzis BC, et al. A review of complications following transvaginal oocyte retrieval for in-vitro fertilization. Human Reproduction. 2004.
3. American Society for Reproductive Medicine. Repetitive oocyte donation: a committee opinion. 2020.
4. Buisman ETI, de Bruin JP, Braat DDM, van der Steeg JW. Effect of needle diameter on pain during oocyte retrieval—a randomized controlled trial. Fertility and Sterility. 2021;115(3):683–691.
5. Wikland M, Blad S, Bungum L, Hillensjö T, Karlström PO, Nilsson S. A randomized controlled study comparing pain experience between a newly designed needle with a thin tip and a standard needle for oocyte aspiration. Human Reproduction. 2011;26(6):1377–1383.
6. Reduced needle versus standard needle for oocyte retrieval: systematic review and meta-analysis of randomized controlled trials. Journal of Assisted Reproduction and Genetics. 2021.
7. Ott J, et al. Severe haematoperitoneum caused by ovarian bleeding after transvaginal oocyte retrieval: a retrospective analysis and systematic literature review.
8. FDA. How are reusable medical devices reprocessed? U.S. Food and Drug Administration.
9. FDA. Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling. U.S. Food and Drug Administration. 2015.
10. World Health Organization. Health products policy and standards: medical-device quality, safety and regulatory systems.
11. ESHRE. Recommendations for good practice in IVF laboratory practice, including oocyte retrieval and processing. Human Reproduction. 2026.